Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT07114861 is registered in ClinicalTrials.gov with New Cancer Cure-Bio Co.,Ltd. as lead sponsor.

NCT NCT07114861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07114861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
New Cancer Cure-Bio Co.,Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 16, 2025
Completion date
October 22, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic pancreatic ductal adenocarcinoma (pdac)